Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6%
Financings Routine −

Hemostemix' $1,000,000 Private Placement and Update

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

By The Northwire Desk — AI Analysis Jun 17, 2026 · 17:23 HEM · 0.055 Hemostemix Inc.
Executive Summary
  • On June 17, 2026, Hemostemix announced the closing of a $1,000,000 private placement priced at $0.05 per unit, comprising common shares and warrants.
  • The company simultaneously filed restated unaudited interim financial statements and MD&A for the nine months ended September 30, 2025.
  • The restatement was triggered by a material misstatement in the accounting treatment of Therapeutic Convertible Debentures (TCDs), which are now classified as Fair Value Through Profit or Loss (FVTPL) under IFRS 9.
  • Adjustments are primarily non-cash, affecting liabilities, professional fees, foreign exchange, and finance expenses, with no direct impact on cash position or business strategy.
  • The original Q3 2025 statements filed on November 28, 2025, are explicitly declared no longer reliable.
Material Impact
  • The $0.05 placement price represents a ~50% discount to prior private placements priced at $0.11–$0.125, signaling acute liquidity stress and a loss of pricing power in the capital markets.
  • The financial restatement, while non-cash, highlights internal control weaknesses and undermines historical financial credibility. The voiding of Q3 2025 statements complicates investor and partner due diligence.
  • Dilution is severe: the new issuance adds to an existing overhang of 106 million warrants and 14.3 million options, further pressuring the share count.
  • The $1M raise only partially covers the $1.37M working capital deficit and ongoing quarterly burn, meaning the company will likely need additional capital within 6–12 months.
HEM · Price
Company Overview
  • Hemostemix Inc. is a pre-revenue clinical-stage biotech developing ACP-01 (VesCell), an autologous angiogenic cell precursor therapy.
  • Target indications include chronic limb-threatening ischemia (CLTI), refractory angina, cardiomyopathy, and vascular dementia.
  • Commercialization efforts are underway in Florida (under SB 1768), The Bahamas, and Canada, with a strategic focus on underserved and Indigenous communities.
  • The company is advancing a Phase 1 basket protocol following FDA pre-IND feedback, aiming to evaluate ACP-01 across multiple ischemic and vascular conditions.
Read the original news release →

More from Hemostemix Inc.

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Mar 09, 2026 · 11:24

Hemostemix Leadership Attending Abundance360 Summit

Management Feb 03, 2026 · 19:02

Hemostemix appoints Hsiang as business consultant

Management Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory